154 related articles for article (PubMed ID: 8828744)
1. The Alpha trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease. Alpha International Coordinating Committee.
AIDS; 1996 Jul; 10(8):867-80. PubMed ID: 8828744
[TBL] [Abstract][Full Text] [Related]
2. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group.
Jablonowski H; Arasteh K; Staszewski S; Ruf B; Stellbrink HJ; Schrappe M; Stoehr A; Haase W; Schomaker U; von Eisenhart Rothe B
AIDS; 1995 May; 9(5):463-9. PubMed ID: 7639971
[TBL] [Abstract][Full Text] [Related]
3. Once versus twice daily administration of didanosine in children with symptomatic HIV-associated disease who were intolerant to or clinically deteriorated on zidovudine. The Italian Pediatric Collaborative Study Group on Didanosine.
Marchisio P; Principi N; Gabiano C; Galli L; Gattinara GC; Caselli D; Zuccotti G; La Regina A; Paga C
Antivir Ther; 1997 Jan; 2(1):47-55. PubMed ID: 11322266
[TBL] [Abstract][Full Text] [Related]
4. Italian multicentre study of didanosine compassionate use in advanced HIV infection. Italian BMS-906 Study Group.
d'Arminio Monforte A; Musicco M; Galli M; Paga C; La Regina A; Lazzarin A; Angarano G; Milazzo F; Gritti F; Arlotti M; Mazzotta F; Visco G; Aiuti F; Moroni M
Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):135-42. PubMed ID: 9105840
[TBL] [Abstract][Full Text] [Related]
5. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
Rathbun RC; Martin ES
Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection.
Floridia M; Vella S; Seeber AC; Tomino C; Fragola V; Weimer LE; Ricciardulli D; Milazzo F; Gritti FM; Mazzotta F; Ranieri S; Chiodo F; Moroni M; Cargnel A; Bassetti D; Giannini V; Cremoni L; Concia E; Sinicco A; Carosi G; Alberici F; Dianzani F
J Infect Dis; 1997 Feb; 175(2):255-64. PubMed ID: 9203645
[TBL] [Abstract][Full Text] [Related]
7. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
[TBL] [Abstract][Full Text] [Related]
8. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
[TBL] [Abstract][Full Text] [Related]
9. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
McKinney RE; Johnson GM; Stanley K; Yong FH; Keller A; O'Donnell KJ; Brouwers P; Mitchell WG; Yogev R; Wara DW; Wiznia A; Mofenson L; McNamara J; Spector SA
J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
[TBL] [Abstract][Full Text] [Related]
10. A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals.
Gatell JM; Leal M; Mallolas J; Vidal C; Pumarola T; Parra R; Padró S; Caruz A; Falgueras T; Rey C; Sánchez-Quijano A; Torres Y; Lissen E; Jiménez de Anta MT; Soriano E
Antivir Ther; 1996 Apr; 1(2):105-12. PubMed ID: 11321180
[TBL] [Abstract][Full Text] [Related]
11. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial Groups.
Ragni MV; Amato DA; LoFaro ML; DeGruttola V; Van Der Horst C; Eyster ME; Kessler CM; Gjerset GF; Ho M; Parenti DM
Blood; 1995 May; 85(9):2337-46. PubMed ID: 7727768
[TBL] [Abstract][Full Text] [Related]
12. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
D'Aquila RT; Hughes MD; Johnson VA; Fischl MA; Sommadossi JP; Liou SH; Timpone J; Myers M; Basgoz N; Niu M; Hirsch MS
Ann Intern Med; 1996 Jun; 124(12):1019-30. PubMed ID: 8633815
[TBL] [Abstract][Full Text] [Related]
13. Double-blind placebo-controlled pilot trial of acemannan in advanced human immunodeficiency virus disease.
Montaner JS; Gill J; Singer J; Raboud J; Arseneau R; McLean BD; Schechter MT; Ruedy J
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jun; 12(2):153-7. PubMed ID: 8680886
[TBL] [Abstract][Full Text] [Related]
14. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
Lancet; 1996 Aug; 348(9023):283-91. PubMed ID: 8709686
[TBL] [Abstract][Full Text] [Related]
15. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
Mulder JW; Cooper DA; Mathiesen L; Sandström E; Clumeck N; Gatell JM; French M; Donovan B; Gray F; Yeo JM
AIDS; 1994 Mar; 8(3):313-21. PubMed ID: 7913326
[TBL] [Abstract][Full Text] [Related]
16. Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team.
Currier JS; Spino C; Grimes J; Wofsy CB; Katzenstein DA; Hughes MD; Hammer SM; Cotton DJ
J Acquir Immune Defic Syndr; 2000 Aug; 24(4):316-24. PubMed ID: 11015147
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
[TBL] [Abstract][Full Text] [Related]
18. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
Kelleher T; Cross A; Dunkle L
Clin Ther; 1999 Jul; 21(7):1182-92. PubMed ID: 10463516
[TBL] [Abstract][Full Text] [Related]
19. Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.
Montaner JS; Schechter MT; Rachlis A; Gill J; Beaulieu R; Tsoukas C; Raboud J; Cameron B; Salomon H; Dunkle L; Smaldone L; Wainberg MA
Ann Intern Med; 1995 Oct; 123(8):561-71. PubMed ID: 7677296
[TBL] [Abstract][Full Text] [Related]
20. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
Gatell JM; González-Lahoz J; Clotet B; Antunes F; Kasparova L; Gil-Aguado A; Saballs P; Santamaria JM; Podzamczer D; Miro JM; Jou A; Verdejo J; Doroana M; Thomis J
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):249-58. PubMed ID: 8673528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]